Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index: 18-30 kg/m\^2~* Body Weight 60-80 kg~* Participant with both a normal stomach and proximal duodenum mucosa as evidenced by endoscopic results~Exclusion Criteria:~* Participant with evidence of current/active, or a history of gastrointestinal disease~* Participant with a history of renal disease, pulmonary edema, cardiomyopathy, liver disease, intrinsic coagulation defects, bleeding diseases or anticoagulant therapy~* Participant with a history of using antacids, H2 receptor antagonists, proton pump inhibitors, or misoprostol more than twice a month or has used any of these medications within 1 week of Visit 1.~* Participant with a current or recurrent disease, within 12 months of Visit 1, that could affect the action, absorption, disposition, or excretion of the study treatments or evaluation of the clinical or laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Paracetamol Tablet (Type: ACTIVE_COMPARATOR): Paracetamol 500 mg tablet, 2 tablets administered 4 times a day (QID) with water.
- Ibuprofen Tablet (Type: ACTIVE_COMPARATOR): Ibuprofen 400 mg tablet, 2 tablets administered three times a day (TID) with water
- Placebo Tablet (Type: PLACEBO_COMPARATOR): Placebo tablets, 2 tablets QID administered with water.
- Ibuprofen Capsule (Type: ACTIVE_COMPARATOR): Ibuprofen 400 mg liquid gel capsules, 2 tablets, TID administered with water

Based on this trial design, predict the completion outcome and termination type (if applicable).